REGEN-COV sales fluctuated as new SARS-CoV-2 variants emerged
Publicly reported sales of the Covid-19 antibody REGEN-COV (casirivimab and imdevimab)
2020
2021
2022
2023
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
2,000
2,200
2,400
2,600
2,800
3,000
Sales ($millions)
Sales ($millions)
GlobalData
